Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma

Clinica Chimica Acta

Volumn 413, Issue 1-2, 2012, Pages 143-149

  Götze, Lutz ^a   Hegele, Axel ^a   Metzelder, Stephan Klaus ^a   Renz, Harald ^a   Nockher, Wolfgang Andreas ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Liquid chromatography; Mass spectrometry; Multi parameter analysis; Plasma; Quantification; Tyrosine kinase inhibitors

Indexed keywords

ACETONITRILE; AMMONIUMFORMIATE; ERLOTINIB; FORMIC ACID; FORMIC ACID DERIVATIVE; IMATINIB; LAPATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CALIBRATION; CHEMICAL REACTION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG STRUCTURE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY CANCER; LIQUID CHROMATOGRAPHY; MALE; PRECIPITATION; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 82955248118     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.09.012     Document Type: Article

References (36)

1. Comiglio P.M., Di Renzo M.F., Gaudino G. Protein tyrosine kinases associated with human malignancies. Ann NY Acad Sci 1987, 511:256-261.
2. Capdeville R., Buchdunger E., Zimmermann J., et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002, 1:493-502.
3. Krause D.S., van Etten R.A. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005, 353:172-187.
4. van Erp N.P., Gelderblom H., Guchelaar H.J. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 2009, 35:692-706.
5. Matulonis U.A., Berlin S., Ivy P., et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009, 27:5601-5606.
6. Blumenstein G.R., Reckamp K., Stephenson G.J., et al. Phase 1b study of motesanib, an oral angiogensis inhibitor, in combination with carboplatin/paclitaxel and/or panitumzmab for the treatment of advanced non-small cell lung cancer. Clin Cancer Res 2010, 16:279-290.
7. Wong K.K., Fracasso P.M., Bukowski R.M., et al. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 2009, 15:2552-2558.
8. Eskens F.A., Steeghs N., Verweij J., et al. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors. J Clin Oncol 2009, 27:4169-4176.
9. Reardon D.A., Egorin M.J., Desjardins A., et al. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea from malignant glioma. Cancer 2009, 115:2188-2198.
10. Yin O.Q.P., Gallagher N., Li A., Zhou W., Harrell R., Schran H. Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol 2010, 50:188-194.
11. Visentin M., Biason P., Toffoli G. Drug interactions among the epidermal growth factor receptor inhibitors, other biological and cytotoxic agents. Pharmacol Ther 2010, 128:82-90.
12. Joensuu H., Trent J.C., Reichardt P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat Rev 2010, 37:75-88.
13. Frankel C., Palmieri F.M. Lapatinib side-effect management. Clin J Oncol Nurs 2010, 14:223-233.
14. Blay J.Y. Pharmacological management of gastrointestinal stromal tumors: an update on the role of sunitinib. Ann Oncol 2010, 21:208-215.
15. Mendel D.B., Douglas A., Xin X., et al. The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effects. Clin Cancer Res 2006, 12:6203-6204.
16. Widmer N., Béguin A., Rochat B., et al. Determination of imatinib (Gleevec®) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci 2004, 803:285-292.
17. Haouala A., Zanolari B., Rochat B. Therapeutic drug monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:1982-1996.
18. Honeywell R., Yarzadah K., Giovannetti E., et al. Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010, 878:1059-1068.
19. De Francia S., D'Avolia A., De Martino F., et al. New HPLC-MS method for the simultaneous quantification of the anitleukemia drugs imatinib, dasatinib and nilotinib in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:1721-1726.
20. Haura E.B., Tanvetyanon T., Chiappori A., et al. Phase I//I study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small cell lung cancer. J Clin Oncol 2010, 28:1387-1394.
21. Demetri G.D., Casali P.G., Blay J.Y., et al. A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res 2009, 15:5910-5916.
22. Bouchet S., Chauzit E., Ducint N., et al. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid phase extraction and ultra performance LC/MS-MS. Clin Chim Acta 2011, 412:1060-1067.
23. U.S.Department of Health and Human Services, Food, Drug Administration (FDA), Center for Drug Evaluation Research (CDER) Guidance for Industry, Bioanalytical Method Validation May 2001.
24. Shah V.P., Midha K.K., Findlay J.W.A., et al. Bioanalytical method validation - a revisit with a decade of progress. Pharm Res 2000, 17:1551-1557.
25. Gotink K.J., Verheul Henk M.W. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?. Angiogenesis 2010, 13:1-14.
26. Metzelder S.K., Wollmer E., Neubauer A., Burchert A. Sorafenib in relapsed and refractory FLT3-ITD positive acute myeloid leukemia: a novel treatment option. Dtsch Med Wochenschr 2010 Sep, 135(38):1852-1856.
27. Metzelder S.K., Wang Y., Wollmer E., et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogenic stem cell transplantation. Blood 2009, 113:6567-6571.
28. Picard S., Titier K., Etienne G., et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007, 109:3496-3499.
29. Buclin T., Gotta V., Widmer N., et al. Schweiz Med Forum 2010, 10:403-406.
30. Faivre S., Delbaldo C., Vera K., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006, 24:25-35.
31. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic, relationship. Clin Cancer Res 2003, 9:327-337.
32. Hartmann J.T., Haap M., Kopp H.G., Lipp H.P. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009, 10:470-478.
33. Quintas-Cardama A., Han X., Kantarjian H., Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukaemia. Blood 2009, 114:261-263.
34. Ghofrani H.A., Morrell N.W., Hoeper M.M., et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010, 182(9):1171-1177.
35. Cohen S., Fleischmann R. Kinase inhibitors: a new approach to rheumatoid arthritis treatment. Curr Opin Rheumatol 2010, 22:330-335.
36. Humbert M., de Blay F., Garcia G., et al. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticoid-dependent asthmatics. Allergy 2009, 64:1194-1201.